Drug intelligence / Profile preview

LY4088044

Development stage: Phase 1
Lead developer: Eli Lilly
Administration: Subcutaneous, Intravenous

Overview

LY4088044 is an experimental pharmaceutical drug developed by Eli Lilly and Company. It is currently being evaluated in a Phase 1 study for its safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamics (how the drug affects the body) in healthy participants. The drug is administered via subcutaneous (under the skin) or intravenous (into a vein) routes. As of September 2025, its precise molecular modality and mechanism of action, as well as its therapeutic indication(s), have not been publicly disclosed[1][3][5].

Other names: LY4088044LY-4088044LY 4088044

Beyond the preview

Go deeper on LY4088044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4088044.

Explore the full profile